Metabolic changes promoting cell survival are involved in metastatic
melanoma progression and in the development of drug resistance. In BRAF-inhibitor resistant
melanoma cells, we explored the role of FASN, an
enzyme involved in lipogenesis overexpressed in metastatic
melanoma. Resistant
melanoma cells displaying enhanced migratory and pro-invasive abilities increased sensitivity to the BRAF inhibitor
PLX4032 upon the molecular targeting of FASN and upon treatment with the FASN inhibitor
orlistat. This behavior was associated with a marked apoptosis and
caspase 3/7 activation observed for the
drug combination. The expression of FASN was found to be inversely associated with drug resistance in BRAF-mutant cell lines, both in a set of six resistant/sensitive matched lines and in the
Cancer Cell Line Encyclopedia. A favorable drug interaction in resistant cells was also observed with U18666 A inhibiting DHCR24, which increased upon FASN targeting. The simultaneous combination of the two inhibitors showed a synergistic interaction with
PLX4032 in resistant cells. In conclusion, FASN plays a role in BRAF-mutated
melanoma progression, thereby creating novel therapeutic opportunities for the treatment of
melanoma.